Enliven Therapeutics CMO Helen Louise Collins disposes of USD 250,000 in common shares

• Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares at $2.48 on Sept. 17, 2026.
• Collins sold 5,000 shares the same day at weighted average prices of $50.03, $50.71, and $51.48.
• Beneficial ownership in common stock ended at 25,000 shares following the transactions.
• Derivative holdings show 106,268 stock options remaining after the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000013), on September 21, 2026, and is solely responsible for the information contained therein.